Trillium Asset Management LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,265 shares of the medical research company's stock after selling 1,855 shares during the quarter. Trillium Asset Management LLC's holdings in IQVIA were worth $12,629,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of IQV. Assetmark Inc. increased its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after buying an additional 196 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of IQVIA during the third quarter worth approximately $230,000. Empowered Funds LLC boosted its holdings in shares of IQVIA by 33.9% during the third quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company's stock worth $814,000 after acquiring an additional 871 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of IQVIA by 20.6% during the third quarter. Thrivent Financial for Lutherans now owns 43,177 shares of the medical research company's stock worth $10,231,000 after acquiring an additional 7,369 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of IQVIA by 0.4% during the third quarter. Swiss National Bank now owns 540,780 shares of the medical research company's stock worth $128,149,000 after acquiring an additional 1,900 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on IQV shares. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Barclays reduced their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $249.05.
Get Our Latest Stock Report on IQV
IQVIA Price Performance
Shares of NYSE:IQV traded up $1.59 during trading on Friday, hitting $185.85. 3,242,588 shares of the company were exchanged, compared to its average volume of 1,239,812. The business's 50 day moving average is $194.94 and its 200-day moving average is $208.45. The company has a market capitalization of $32.77 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $254.54.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
